IGF-1LR3: The Complete Guide

IGF-1 LR3 occupies a distinct position in peptide research. It is neither a growth hormone secretagogue nor a direct anabolic hormone — it is a modified analog of a naturally occurring growth factor, engineered specifically to extend activity and reduce binding interference. Researchers interested in body composition, recovery, and growth signaling have studied it extensively, and it remains one of the more frequently discussed peptides in contexts where GH pathway optimization is the focus.

This guide covers what IGF-1 LR3 is, how it works mechanistically, how it compares to related compounds, what the relevant safety cIGF-1 LR3: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. IGF-1 LR3 is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

IGF-1 LR3 sits downstream of almost every other compound in this guide series — it’s not a growth hormone secretagogue like CJC-1295 or Ipamorelin, it’s the thing those compounds are ultimately trying to produce more of. Understanding that distinction, and a genuine blood sugar consideration that isn’t optional to understand, matters more here than for almost any other compound covered in this library.

Quick Facts

Class	Synthetic IGF-1 analog
Structure	Native IGF-1 with an Arg3 substitution and a 13-amino-acid N-terminal extension
Primary research use	Lean mass retention, recovery, nutrient partitioning
Administration	Subcutaneous or intramuscular
Half-life	~20–30 hours (versus minutes for native IGF-1)
Typical effective range (community-reported)	20mcg–100mcg once daily
Evidence tier	Real, extensive preclinical mechanism data; no completed human muscle or body-composition trials
Regulatory status	Not approved anywhere as a research compound; a related but distinct molecule (mecasermin) holds narrow pediatric FDA approval

The 60-Second Version

• IGF-1 LR3 works downstream of compounds like CJC-1295 and Ipamorelin — it activates the same receptor those compounds are trying to produce more signal for, rather than triggering your pituitary to release anything.
• It reliably lowers blood sugar, independent of food or your own insulin. This is a core mechanism, not a rare side effect, and it’s the single most important thing to prepare for before your first dose.
• No human trial has tested it for muscle growth, recovery, or body composition — everything you’ll read about those outcomes is community report or animal data, not clinical evidence.
• It needs acetic acid, not plain BAC water, to reconstitute properly — the one real exception to the standard approach used everywhere else in this guide series.
• Reconstituted solution is good for roughly 2–4 weeks, not the usual 28 days.

The Story So Far

IGF-1 LR3 wasn’t built to become a research-community staple — it was built in the early 1990s to solve a specific laboratory problem. Native IGF-1 binds tightly to a family of proteins called IGF binding proteins (IGFBPs), which sequester it in circulation and limit how much reaches receptors at any given time. That tight binding gives native IGF-1 an active half-life measured in minutes to a few hours — useful biologically, but impractical for researchers trying to study what sustained IGF-1 receptor activation actually does. IGF-1 LR3 was engineered specifically to get around that limitation: an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus together reduce IGFBP binding affinity by several orders of magnitude, while leaving the compound’s ability to activate the IGF-1 receptor itself intact. The result is a research tool with a half-life in the range of 20 to 30 hours — an order of magnitude longer than the molecule it’s derived from.

It’s worth being precise about a related but genuinely different compound you’ll encounter if you search further: mecasermin, sold under the brand name Increlex, is a recombinant form of native, unmodified human IGF-1, FDA-approved for a narrow pediatric indication — severe primary IGF-1 deficiency, or growth hormone gene deletion with GH antibodies, in children with open growth plates. Increlex’s approval doesn’t transfer to IGF-1 LR3 — different molecule, different modification, different population, different indication entirely, and Increlex’s label specifically loses its approved indication once growth plates close, meaning there’s no validated adult use case even for the approved molecule, let alone the research analog. If you see IGF-1 LR3 marketed with confidence borrowed from IGF-1’s general pharmaceutical legitimacy, this is the distinction that confidence is skipping over.

What It Actually Does

IGF-1 LR3 binds to and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase expressed across muscle, fat, and connective tissue. That binding triggers the PI3K/Akt/mTOR signaling cascade — one of the body’s central pathways governing cell growth, protein synthesis, and survival, and the same pathway dietary protein and resistance training converge on to drive muscle adaptation. Because IGF-1 LR3 evades IGFBP sequestration so effectively, a much larger proportion of the compound remains in its free, receptor-active form for a much longer window than native IGF-1 ever achieves — that’s the entire mechanistic basis for its research interest.

A genuinely important second half of this mechanism, and the reason this compound needs to be discussed with real care rather than just enthusiasm: IGF-1 shares real structural and functional overlap with insulin, both having evolved from a common ancestral molecule. IGF-1 LR3 activates glucose uptake through the same PI3K/Akt pathway insulin uses, which means it lowers blood glucose — independent of food intake or your own insulin levels. This isn’t a minor side note buried in a side-effects list; it’s a core part of what the compound does mechanistically, and it shapes almost everything about how it needs to be handled practically.

What the Research Shows

The evidence picture here follows a pattern that should feel familiar from elsewhere in this guide series: extensive, legitimate mechanistic and animal research, and an almost complete absence of human trials for the outcomes people are actually interested in.

The receptor pharmacology is genuinely well-characterized. IGF-1 LR3’s reduced IGFBP binding and preserved IGF-1R activity are well-documented, consistent findings across cell culture and animal studies, and the PI3K/Akt/mTOR downstream cascade it triggers is one of the most thoroughly mapped signaling pathways in cell biology generally.

The animal safety data includes three findings worth sitting with individually:

• A frequently cited 1995 study (Conlon, Tomas, and colleagues, Journal of Endocrinology) found that just seven days of continuous IGF-1 LR3 infusion in guinea pigs produced significant organ growth alongside reduced circulating IGF-1, IGF-2, and IGF binding protein concentrations — real organ-level change from a relatively short exposure window.
• A separate 1997 study from the same Adelaide-based research group found that IGF-1 LR3 infusion in pigs reduced growth hormone output by 23% and suppressed endogenous IGF-1, IGFBP-3, and insulin concentrations. This is the basis for the community practice of keeping off-cycle periods three to four times longer than on-cycle periods.
• Standard rat carcinogenicity data referenced in the Increlex (mecasermin) drug label found increased mammary and skin tumor incidence at high IGF-1 exposure — a standard part of that drug’s regulatory safety package, and a concrete, specific data point behind the cancer-related caution discussed later in this guide, not just a theoretical one.

Completed human trials specific to IGF-1 LR3, for the outcomes it’s actually researched for, do not exist. No published, controlled human study has evaluated IGF-1 LR3 for muscle growth, body composition, or recovery outcomes. What circulates as “results” for this compound is exclusively community-reported experience and animal data — a genuinely different evidentiary situation than compounds elsewhere in this guide series that at least have a mismatched or unpublished human trial to point to. Here, there simply isn’t one.

How It Compares

IGF-1 LR3 occupies a different position in the growth hormone axis than CJC-1295, Ipamorelin, and Tesamorelin — rather than stimulating the pituitary to produce more growth hormone (which then drives the liver to produce IGF-1), IGF-1 LR3 skips that entire upstream cascade and activates the IGF-1 receptor directly.

	IGF-1 LR3	CJC-1295 + Ipamorelin	Tesamorelin
Pathway entry point	Downstream — direct IGF-1R activation	Upstream — pituitary GH stimulation	Upstream — pituitary GH stimulation
Preserves natural GH pulsatility	No — bypasses it entirely	Yes	Yes
Blood sugar effect	Significant	Modest	Modest
Human trial history	None, for its own research use case	Mismatched or absent, covered in each compound’s own guide	Full Phase 3 program; FDA-approved
Primary research interest	Lean mass retention, recovery, nutrient partitioning	Recovery, sleep, body composition	Visceral fat reduction specifically

The practical distinction worth understanding: the secretagogue approach works with the body’s own regulatory machinery, preserving the natural pulsatile release pattern and the feedback loops that come with it. IGF-1 LR3 works around that machinery, activating the downstream receptor directly and more bluntly. Neither approach is simply “better” — they’re addressing different points in the same axis, which is exactly why they’re so often discussed together rather than as alternatives to each other.

Who Shouldn’t Use This

IGF-1 LR3 has no approved label of its own, so there’s no official contraindications list — but its real, documented glucose-lowering mechanism makes several of these considerations more concrete than the general cautions that apply elsewhere in this guide series.

• Diabetes, or any condition involving glucose dysregulation. This is a hard, mechanism-based caution, not a generic one. Combining IGF-1 LR3 with existing insulin therapy or impaired glucose handling can produce severe, unpredictable hypoglycemia.
• Concurrent insulin or insulin secretagogue therapy, for the same reason.
• Personal or family history of hormone-sensitive cancer, or active malignancy. IGF-1 receptors are overexpressed in many tumor types, and IGF-1R activation is associated with cell survival signaling that can theoretically support existing tumor growth. Epidemiological research has found associations between chronically elevated endogenous IGF-1 and increased risk of certain cancers — correlational, not proof of causation, but a real enough signal that this deserves individual medical assessment rather than a passing mention.
• Adolescents with open growth plates. Disproportionate growth is a genuine concern in this population, and unsupervised research use here isn’t appropriate.
• Pregnancy or breastfeeding. No human safety data exists in this context.

Anyone in any of these categories should treat this as a conversation with a healthcare provider, not a research decision to make alone.

If You Feel Symptoms of Low Blood Sugar

This is worth having as a concrete, memorized plan rather than something you figure out in the moment.

Early symptoms to watch for: shakiness or trembling, sweating, sudden hunger, dizziness or lightheadedness, a racing heartbeat, and mild anxiety or irritability. These usually appear within the first few hours after a dose.

What to do, in order:

1. Stop what you’re doing — don’t try to push through a workout or drive until this is resolved.
2. Consume 15–20 grams of fast-acting carbohydrate immediately — glucose tablets, juice, or regular soda are standard choices, specifically because they don’t require digestion of fat or protein first.
3. Wait 15 minutes, then reassess. If symptoms haven’t improved, repeat step 2.
4. Once you feel better, eat something with protein or complex carbohydrates to help stabilize levels afterward, rather than stopping at the fast-acting carbohydrate alone.
5. If symptoms progress to confusion, difficulty speaking, loss of coordination, or you lose consciousness, this is a medical emergency — call for emergency help. A caregiver or research partner should know this plan too, since you may not be able to act on it yourself at that stage.

Have a fast-acting carbohydrate source within reach before you inject, every time — not somewhere in the house, but in the room where you’re planning to notice symptoms.

Common Myths, Addressed

“IGF-1 LR3 is basically growth hormone.” Not accurately. Growth hormone acts on the liver to stimulate IGF-1 production, among other separate effects of its own. IGF-1 LR3 acts directly at the IGF-1 receptor, skipping that entire upstream cascade. They sit at different points in the same broader pathway, and using one doesn’t replicate the full effect of the other.

“More IGF-1 activity means more muscle.” IGF-1 signaling is one input into a much larger system. Without training stimulus and adequate protein and calorie intake, there’s no underlying anabolic signal for IGF-1R activation to amplify — the compound is an adjunct to a real protocol, not a substitute for one.

“It’s safe because it’s ‘just’ a peptide.” The peptide category is enormous and says nothing about risk level on its own. IGF-1 LR3 has real, mechanism-based effects on blood glucose that require genuine preparation, not casual dismissal.

What Researchers Are Actually Experiencing

Because there’s no human trial data to check community experience against, what’s reported here carries more interpretive weight than usual — and it’s worth reading accordingly.

The most consistently reported subjective effect is a sensation of muscle “fullness” or pump during and immediately after training — a pattern that’s at least mechanistically plausible given IGF-1’s known effects on intracellular hydration, though it’s not something a controlled trial has confirmed specific to this compound. Some researchers describe modestly improved training capacity — extra repetitions, faster recovery between sets — which is squarely anecdotal.

Water retention, presenting as mild puffiness particularly in the extremities, is commonly reported and is consistent with IGF-1’s known effects on sodium and fluid handling. Headaches are occasionally mentioned, plausibly tied to the same fluid shifts or to blood glucose fluctuation.

This section reflects patterns commonly discussed across community research spaces. It’s observational, not clinical trial data, and — more than for most compounds in this guide series — there’s no trial data available to cross-check it against at all.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Standard	20–100mcg	Once daily

No human clinical trial has validated a specific dosing range for this compound — the range above reflects what’s commonly discussed in community practice, not an evidence-derived recommendation. Most community protocols cap active use at four to six weeks, followed by an off-period at least as long, often longer, before any subsequent cycle — directly informed by the endogenous IGF-1 suppression finding described above.

Worked Dose Math

At 1mg/mL (a 1mg vial reconstituted with 1mL of dilute acetic acid solution — see the reconstitution note below):

• 20mcg (0.02mg) → 0.02mL → 2 units
• 50mcg (0.05mg) → 0.05mL → 5 units
• 100mcg (0.1mg) → 0.1mL → 10 units

The underlying rule is the same as any other compound: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe. Convert micrograms to milligrams before applying the formula.

Vial Planning

A 1mg vial at 1mg/mL gives you 1mg (1,000mcg) total. At a steady 50mcg/day, that’s 20 days per vial — comfortably covering a standard 4-week cycle.

Reconstitution and Storage — The Real Deviation

This is the one compound in this guide series that genuinely doesn’t follow the standard BAC-water approach, and it’s worth understanding why. IGF-1 LR3 is more stable in mildly acidic conditions, and reconstituting it in neutral or basic solutions — standard bacteriostatic water — can cause degradation or aggregation. The common approach is reconstitution with a dilute acetic acid solution (roughly 0.1%–1%), either prepared directly or as BAC water with a small measured amount of acetic acid added. Follow your specific supplier’s guidance here rather than assuming the standard approach used elsewhere in this guide series applies.

Storage also deviates from the usual pattern: lyophilized IGF-1 LR3 should be kept frozen (−20°C or below) and protected from light, rather than simply refrigerated. Once reconstituted, it’s considerably less stable than most other compounds in this series — refrigerate at 2–8°C and use within roughly two to four weeks, notably shorter than the 28-day window that applies to nearly everything else covered in this guide series. Avoid vigorous shaking during reconstitution; gentle swirling or rolling is appropriate, the same as always.

Sourcing

Nothing beyond the general picture applies here — see our full guide on reading a Certificate of Analysis and vetting a vendor. Given this compound’s specific reconstitution requirements, it’s worth confirming your vendor’s guidance on acetic acid concentration specifically rather than assuming a generic answer applies.

Administration

Subcutaneous or intramuscular injection, once daily given the extended half-life. No fasting requirement, though awareness of your last meal and blood glucose status matters more here than for most compounds in this guide series.

Best Practices

• Have a fast-acting carbohydrate source on hand before your first dose, and every dose after — this is a basic, non-optional precaution given the compound’s real glucose-lowering effect.
• Review the low blood sugar action plan above before your first dose, not after you feel symptoms.
• Plan your off-cycle before you start your on-cycle, given the documented endogenous suppression effect — this isn’t a detail to figure out later.
• Confirm your reconstitution approach with your specific supplier, since this compound doesn’t follow the standard BAC-water pattern used elsewhere.
• Track your protocol from day one — dose, timing, and any glucose-related symptoms, at minimum.

Common Mistakes to Avoid

• Reconstituting with plain BAC water the way you would almost any other compound in this guide series — this compound specifically needs an acidic reconstitution environment.
• Underestimating the blood sugar effect because the compound is a peptide rather than a more obviously “medical” substance like insulin.
• Not having a plan for symptoms before they occur, rather than researching hypoglycemia management only after feeling unwell.
• Skipping or shortening the off-cycle, given the real, documented endogenous suppression this compound produces.
• Assuming Increlex’s FDA approval says anything about IGF-1 LR3’s safety or efficacy — they’re different molecules with different modifications, approved for different reasons.

What Happens If You Stop

The relevant finding here isn’t about stopping so much as what continued or repeated use does to your own IGF-1 production: animal research found that IGF-1 LR3 use suppresses endogenous IGF-1 output, which is the entire rationale behind the community-standard practice of an extended off-cycle. Whether or how long that suppression persists in humans, and what a “recovery” period should actually look like, hasn’t been established in a controlled human trial — the 3–4x-longer-off-cycle guideline is a reasonable, cautious inference from the animal data, not a validated human finding.

What to Expect, Week by Week

• Days 1–7: Water retention and, for some researchers, a sensation of muscle fullness during training are the most commonly reported early observations.
• Weeks 2–4: Community reports of improved training capacity or recovery, where present, tend to appear in this window — entirely anecdotal, with no trial data to benchmark against.
• End of cycle (weeks 4–6): Most community protocols conclude an active cycle here, moving into the extended off-period before any subsequent cycle.

Individual timelines vary substantially, and — more than for almost any compound in this guide series — this pattern comes entirely from community report, since no human trial exists to check it against.

Combining With Other Compounds

IGF-1 LR3 is most frequently discussed alongside CJC-1295 and Ipamorelin, on a straightforward mechanistic rationale: the secretagogue combination drives the upstream GH pathway, while IGF-1 LR3 activates the downstream receptor directly, addressing both ends of the same axis simultaneously. A similar rationale is discussed for pairing it with Tesamorelin, particularly where visceral fat reduction is a specific objective. It’s also sometimes discussed alongside BPC-157 and TB-500 in recovery-focused contexts, on the logic that the mechanisms address recovery from different angles — a reasonable hypothesis worth your own research, not an established combination protocol with trial support.

Common Questions

Is IGF-1 LR3 the same as growth hormone? No — growth hormone acts on the liver to produce IGF-1 as one of several downstream effects. IGF-1 LR3 activates the IGF-1 receptor directly, bypassing that entire pathway.

Is IGF-1 LR3 the same as Increlex (mecasermin)? No — Increlex is recombinant native IGF-1, approved narrowly for pediatric IGF-1 deficiency. IGF-1 LR3 is a structurally modified analog with no equivalent approval, for a different population and purpose entirely.

Does IGF-1 LR3 actually lower blood sugar, or is that overstated? It’s real and significant, not overstated. This is a core part of the compound’s mechanism, not a rare side effect — preparation for it isn’t optional.

Why does IGF-1 LR3 need a different reconstitution approach than most other compounds? It’s more stable in mildly acidic conditions and can degrade or aggregate in the neutral bacteriostatic water most other compounds use. This is a genuine compound-specific exception, not a matter of preference.

Has this compound been tested in human muscle or body composition trials? No completed, published human trial has evaluated IGF-1 LR3 for these outcomes. What exists is community report and animal research.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Confirmed you don’t have diabetes or another condition affecting glucose regulation, or sought medical guidance if you do
• [ ] Have a fast-acting carbohydrate source on hand and know the symptoms of hypoglycemia
• [ ] Confirmed your reconstitution approach with your supplier, given this compound’s acidic reconstitution requirement
• [ ] Planned your off-cycle length before starting your on-cycle
• [ ] Considered whether you have a personal or family history of hormone-sensitive cancer, and sought medical guidance if so
• [ ] Have a tracking method ready for dose, timing, and any glucose-related symptoms

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Standard	20mcg–100mcg	Once daily

Standard cycle: 4–6 weeks on, followed by an off-period at least as long, often 3–4x longer, before repeating.

Where to Go From Here

• CJC-1295: The Complete Guide
• Ipamorelin: The Complete Guide
• Tesamorelin: The Complete Guide
• The Growth Hormone Axis Group — CJC-1295, Ipamorelin, and Tesamorelin compared in full
• BPC-157 and TB-500 — commonly discussed recovery-focused pairings
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.